Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7P40

P5C3 is a potent fab neutralizer

7NY5」から置き換えられました
7P40 の概要
エントリーDOI10.2210/pdb7p40/pdb
EMDBエントリー13190
分子名称Spike glycoprotein, Variable Light Chain P5C3 (VL), Variable Heavy Chain P5C3 (VH) (3 entities in total)
機能のキーワードspike, antibody, viral protein
由来する生物種Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
詳細
タンパク質・核酸の鎖数9
化学式量合計564935.60
構造登録者
perez, L. (登録日: 2021-07-09, 公開日: 2021-10-13, 最終更新日: 2024-11-20)
主引用文献Fenwick, C.,Turelli, P.,Perez, L.,Pellaton, C.,Esteves-Leuenberger, L.,Farina, A.,Campos, J.,Lana, E.,Fiscalini, F.,Raclot, C.,Pojer, F.,Lau, K.,Demurtas, D.,Descatoire, M.,Joo, V.S.,Foglierini, M.,Noto, A.,Abdelnabi, R.,Foo, C.S.,Vangeel, L.,Neyts, J.,Du, W.,Bosch, B.J.,Veldman, G.,Leyssen, P.,Thiel, V.,LeGrand, R.,Levy, Y.,Trono, D.,Pantaleo, G.
A highly potent antibody effective against SARS-CoV-2 variants of concern.
Cell Rep, 37:109814-109814, 2021
Cited by
PubMed Abstract: Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date. Structural characterization of P5C3 Fab in complex with the spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2-infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals.
PubMed: 34599871
DOI: 10.1016/j.celrep.2021.109814
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3.5 Å)
構造検証レポート
Validation report summary of 7p40
検証レポート(詳細版)ダウンロードをダウンロード

248942

件を2026-02-11に公開中

PDB statisticsPDBj update infoContact PDBjnumon